Date: 2016-06-14
Type of information: Nomination
Compound:
Company: Minoryx Therapeutics (Spain)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On June 14, 2016, Minoryx Therapeutics announced the appointment of Dr. Uwe Meya as Chief Medical Officer (CMO). As a specialist in neurological disorders, Dr. Meya will advance the clinical development of Minoryx’s lead candidate MIN-102 for X-ALD. Dr. Meya is a neurologist and psychiatrist. He has over 30 years of experience in pharmaceutical research and development, with a special focus on central nervous system (CNS) disorders. He has expertise in all aspects of drug development from first-in-man trials to regulatory filing. Minoryx Therapeutics’ MIN-102 is ready to initiate a phase 1 study. It targets the most prevalent peroxisomal disorder, X-linked adrenoleukodystrophy (X-ALD). MIN-102 is a differentiated PPAR gamma agonist with a superior profile for CNS related diseases. Dr. Meya joins Minoryx Therapeutics from Lupin Atlantis Holdings SA (Zug, Switzerland), where he was responsible for clinical strategy and implementation of studies with new clinical entities in various indications, including neurodegenerative disorders. Earlier, Dr. Meya led phase 1 and phase 2 clinical studies in neurodegenerative disorders at Synosia Therapeutics (Basel, Switzerland and San Francisco, CA, USA), which was later acquired by Biotie Therapies (Turku, Finland). Prior to this, Dr. Meya was head of research portfolio management as well as serving as clinical research and licensing liaison manager in CNS at Roche (Basel, Switzerland). Before that, Dr. Meya managed a team of researchers in CNS clinical development at Novartis (Basel, Switzerland), having previously held the positions of head of clinical development in CNS at Knoll AG (Ludwigshafen, Germany) and medical advisor/head of clinical psychiatry at Schering AG (Berlin, Germany). Dr. Meya received his medical degree as well as his doctorate in psychiatry from the University of Aachen (Germany). He is a member of the European College of Neuropsychopharmacology as well as the International Parkinson and Movement Disorder Society and is a founding member of the International College of Geriatric Psychoneuropharmacology.
Financial terms:
Latest news:
